KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinomaNikolaj Frost, Christian Grohé, Jens Kollmeier et al.|Translational Lung Cancer Research|2021Cited by 60
Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancerDaniel Misch, Jens Kollmeier, Torsten Blum et al.|Diagnostic Pathology|2015Cited by 40
Comparison of different semi-automated cfDNA extraction methods in combination with UMI-based targeted sequencingAnna Streubel, Volker Endris, Albrecht Stenzinger et al.|Oncotarget|2019Cited by 19
Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational StudySusann Stephan-Falkenau, Torsten Blum, Joachim Pfannschmidt et al.|International Journal of Molecular Sciences|2022Cited by 11
<p>A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient’s Suitability for Immune Checkpoint Inhibition</p>Michael Wessolly, Fabian Mairinger, Susann Stephan-Falkenau et al.|Cancer Management and Research|2020Cited by 7